Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 10/20 | 0.32 |
| ▸ | FLT1 | P17948 | 9/20 | 0.32 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285231 | 0.86 | GRIN3B (0.35) | KDRFLT1MAP3K8GRIN3BGRIN1 | |
| SCHEMBL2282329 | 0.85 | DYRK1A (0.33) | SCN9A | |
| SCHEMBL29518244 | 0.85 | AXL (0.39) | KDRAXL | |
| SCHEMBL307500 | 0.85 | AXL (0.39) | KDRAXL | |
| SCHEMBL2282096 | 0.81 | MEN1 (0.39) | SMN1; SMN2KDRFLT1GAAALDH1A1 | |
| SCHEMBL2284581 | 0.79 | NPC1 (0.41) | KDRFLT1 | |
| SCHEMBL2602332 | 0.74 | AXL (0.41) | KDRAXL | |
| SCHEMBL2282746 | 0.74 | KDR (0.35) | KDRFLT1 | |
| SCHEMBL13186320 | 0.72 | GRIN2D (0.41) | SMN1; SMN2MAP3K8GAAGRIN3BGRIN1 | |
| SCHEMBL4329985 | 0.72 | ALDH1A1 (0.56) | SMN1; SMN2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1989211-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | SMN1; SMN2 2264/4885KDR 419/4885FLT1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.